177 related articles for article (PubMed ID: 19350351)
1. Possible involvement of RasGRP4 in leukemogenesis.
Watanabe-Okochi N; Oki T; Komeno Y; Kato N; Yuji K; Ono R; Harada Y; Harada H; Hayashi Y; Nakajima H; Nosaka T; Kitaura J; Kitamura T
Int J Hematol; 2009 May; 89(4):470-481. PubMed ID: 19350351
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.
Oki T; Kitaura J; Watanabe-Okochi N; Nishimura K; Maehara A; Uchida T; Komeno Y; Nakahara F; Harada Y; Sonoki T; Harada H; Kitamura T
Leukemia; 2012 May; 26(5):1038-45. PubMed ID: 22116551
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
4. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
Watanabe-Okochi N; Kitaura J; Ono R; Harada H; Harada Y; Komeno Y; Nakajima H; Nosaka T; Inaba T; Kitamura T
Blood; 2008 Apr; 111(8):4297-308. PubMed ID: 18192504
[TBL] [Abstract][Full Text] [Related]
5. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
[TBL] [Abstract][Full Text] [Related]
6. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
7. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
Yan M; Ahn EY; Hiebert SW; Zhang DE
Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
[TBL] [Abstract][Full Text] [Related]
8. RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia.
Reuther GW; Lambert QT; Rebhun JF; Caligiuri MA; Quilliam LA; Der CJ
J Biol Chem; 2002 Aug; 277(34):30508-14. PubMed ID: 11880369
[TBL] [Abstract][Full Text] [Related]
9. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell.
Shima T; Miyamoto T; Kikushige Y; Yuda J; Tochigi T; Yoshimoto G; Kato K; Takenaka K; Iwasaki H; Mizuno S; Goto N; Akashi K
Exp Hematol; 2014 Nov; 42(11):955-65.e1-5. PubMed ID: 25101977
[TBL] [Abstract][Full Text] [Related]
10. [Activated leukemic oncogenes responsible for neoplastic transformation of hematopoietic cells].
Baskaran D; Spirin PV; Prasolov VS
Mol Biol (Mosk); 2010; 44(3):418-30. PubMed ID: 20608165
[TBL] [Abstract][Full Text] [Related]
11. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
12. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
Matsuno N; Osato M; Yamashita N; Yanagida M; Nanri T; Fukushima T; Motoji T; Kusumoto S; Towatari M; Suzuki R; Naoe T; Nishii K; Shigesada K; Ohno R; Mitsuya H; Ito Y; Asou N
Leukemia; 2003 Dec; 17(12):2492-9. PubMed ID: 14562119
[TBL] [Abstract][Full Text] [Related]
13. RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demonstration of the importance of RasGRP4 in mast cell development and function.
Yang Y; Li L; Wong GW; Krilis SA; Madhusudhan MS; Sali A; Stevens RL
J Biol Chem; 2002 Jul; 277(28):25756-74. PubMed ID: 11956218
[TBL] [Abstract][Full Text] [Related]
14. Ras guanine nucleotide-releasing protein-4 (RasGRP4) involvement in experimental arthritis and colitis.
Adachi R; Krilis SA; Nigrovic PA; Hamilton MJ; Chung K; Thakurdas SM; Boyce JA; Anderson P; Stevens RL
J Biol Chem; 2012 Jun; 287(24):20047-55. PubMed ID: 22511759
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis.
Liu X; Zhang Q; Zhang DE; Zhou C; Xing H; Tian Z; Rao Q; Wang M; Wang J
Leukemia; 2009 Apr; 23(4):739-45. PubMed ID: 19151769
[TBL] [Abstract][Full Text] [Related]
16. FLT3 mutation and AML/ETO in a case of Myelodysplastic syndrome in transformation corroborates the two hit model of leukemogenesis.
Pinheiro RF; Moreira Ede S; Silva MR; Greggio B; Alberto FL; Chauffaille Mde L
Leuk Res; 2007 Jul; 31(7):1015-8. PubMed ID: 17079011
[TBL] [Abstract][Full Text] [Related]
17. Overexpression or knock-down of runt-related transcription factor 1 affects BCR-ABL-induced proliferation and migration in vitro and leukemogenesis in vivo in mice.
Yang LJ; Yu WD; DU JB; Chao S; Chen MX; Zhao HH; Guo JZ
Chin Med J (Engl); 2009 Feb; 122(3):331-7. PubMed ID: 19236814
[TBL] [Abstract][Full Text] [Related]
18. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.
Nishida S; Hosen N; Shirakata T; Kanato K; Yanagihara M; Nakatsuka S; Hoshida Y; Nakazawa T; Harada Y; Tatsumi N; Tsuboi A; Kawakami M; Oka Y; Oji Y; Aozasa K; Kawase I; Sugiyama H
Blood; 2006 Apr; 107(8):3303-12. PubMed ID: 16380455
[TBL] [Abstract][Full Text] [Related]
19. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.
Lin S; Wei J; Wunderlich M; Chou FS; Mulloy JC
Oncotarget; 2016 Aug; 7(35):55939-55950. PubMed ID: 27509060
[TBL] [Abstract][Full Text] [Related]
20. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
